Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411125 | 0.96 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL15732 | 0.96 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL30482572 | 0.94 | KEAP1 (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| Sulfuric Acid SCHEMBL28303863 | 0.94 | KEAP1 (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL9673914 | 0.94 | KEAP1 (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| Hydrochloric Acid SCHEMBL31040251 | 0.94 | GLA (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4022655 | 0.94 | KEAP1 (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL161681 | 0.94 | KEAP1 (0.50) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| Potassium Ion SCHEMBL22188718 | 0.92 | KEAP1 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL8646445 | 0.92 | KEAP1 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552444-B1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL SCIENT IND RES (IN) | 2018-10-10 | — | — | EP | disclosed |
| US-9335332-B2 | Nicotinamide phosphoribosyltransferase (NMPRTase) inhibitor for glioma therapy | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20130274286-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2013-10-17 | — | — | US | disclosed |
| EP-2552444-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | Council of Scientific & Industrial Research (IN) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011121434-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274286-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | NAMPT, NAPRT, NMT1 | KEAP1 1326/4885SMN1; SMN2 2157/4885HPGD 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.